Skip to main content
Erschienen in: Current Hypertension Reports 4/2015

01.04.2015 | Antihypertensive Agents: Mechanisms of Drug Action (ME Ernst, Section Editor)

Personalizing the Diuretic Treatment of Hypertension: the Need for More Clinical and Research Attention

verfasst von: Samuel J. Mann, Michael E. Ernst

Erschienen in: Current Hypertension Reports | Ausgabe 4/2015

Einloggen, um Zugang zu erhalten

Abstract

Neither randomized controlled trials nor efforts to identify genetic markers have been helpful with regard to the goal of individualizing diuretic therapy in the treatment of hypertension, a goal that receives little clinical or research attention. This review will examine, and bring attention to, the considerable yet overlooked information relevant to individualizing diuretic therapy. It will bring attention to clinical, biochemical, and pharmacological clues that can be helpful in identifying who is likely to respond to a diuretic, who needs a stronger diuretic regimen, which diuretic to prescribe, and how to minimize adverse effects. New directions for clinical research aimed at individualizing use in hypertension will be explored. Research and clinical attention to the goal of individualizing diuretic treatment in hypertension need to be renewed, to help us achieve greater hypertension control with fewer adverse effects and lower costs.
Literatur
1.
2.
Zurück zum Zitat Materson BJ. Insights into intrarenal sites and mechanisms of action of diuretic agents. Am Heart J. 1983;106(1 Pt 2):188–208.CrossRefPubMed Materson BJ. Insights into intrarenal sites and mechanisms of action of diuretic agents. Am Heart J. 1983;106(1 Pt 2):188–208.CrossRefPubMed
3.
Zurück zum Zitat Fernandez PC, Puschett JB. Proximal tubular actions of metolazone and chlorothiazide. Am J Physiol. 1973;225(4):954–61.PubMed Fernandez PC, Puschett JB. Proximal tubular actions of metolazone and chlorothiazide. Am J Physiol. 1973;225(4):954–61.PubMed
4.
Zurück zum Zitat Paton RR, Kane RE. Long-term diuretic therapy with metolazone of renal failure and the nephrotic syndrome. J Clin Pharmacol. 1977;17(4):243–51.CrossRefPubMed Paton RR, Kane RE. Long-term diuretic therapy with metolazone of renal failure and the nephrotic syndrome. J Clin Pharmacol. 1977;17(4):243–51.CrossRefPubMed
5.
Zurück zum Zitat Ernst ME, Carter BL, Goerdt CJ, Steffensmeier JJG, Phillips BB, Zimmerman MB, et al. Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension. 2006;47(3):352–8.CrossRefPubMed Ernst ME, Carter BL, Goerdt CJ, Steffensmeier JJG, Phillips BB, Zimmerman MB, et al. Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension. 2006;47(3):352–8.CrossRefPubMed
6.•
Zurück zum Zitat Messerli FH, Makani H, Benjo A, Romero J, Alviar C, Bangalore S. Antihypertensive efficacy of hydrochlorothiazide as evaluated by ambulatory blood pressure monitoring: a meta-analysis of randomized trials. J Am Coll Cardiol. 2011;57:590–600. This meta-analysis demonstrates the prominent dose–response relationship for hydrochlorothiazide, with the relatively modest effect of the 25 mg dose as compared to other drugs. CrossRefPubMed Messerli FH, Makani H, Benjo A, Romero J, Alviar C, Bangalore S. Antihypertensive efficacy of hydrochlorothiazide as evaluated by ambulatory blood pressure monitoring: a meta-analysis of randomized trials. J Am Coll Cardiol. 2011;57:590–600. This meta-analysis demonstrates the prominent dose–response relationship for hydrochlorothiazide, with the relatively modest effect of the 25 mg dose as compared to other drugs. CrossRefPubMed
7.
Zurück zum Zitat Carter BL, Ernst ME, Cohen JD. Hydrochlorothiazide versus chlorthalidone: evidence supporting their interchangeability. Hypertension. 2004;43(1):4–9.CrossRefPubMed Carter BL, Ernst ME, Cohen JD. Hydrochlorothiazide versus chlorthalidone: evidence supporting their interchangeability. Hypertension. 2004;43(1):4–9.CrossRefPubMed
8.••
Zurück zum Zitat Peterzan MA, Hardy R, Chaturvedi N, Hughes AD. Meta-analysis of dose–response relationships for hydrochlorothiazide, chlorthalidone, and bendroflumethiazide on blood pressure, serum potassium, and urate. Hypertension. 2012;59(6):1104–9. This meta-analysis demonstrates how differences between these diuretics in achieved blood pressure are largely attributable to the dose prescribed rather than the drug per se. CrossRefPubMed Peterzan MA, Hardy R, Chaturvedi N, Hughes AD. Meta-analysis of dose–response relationships for hydrochlorothiazide, chlorthalidone, and bendroflumethiazide on blood pressure, serum potassium, and urate. Hypertension. 2012;59(6):1104–9. This meta-analysis demonstrates how differences between these diuretics in achieved blood pressure are largely attributable to the dose prescribed rather than the drug per se. CrossRefPubMed
9.
Zurück zum Zitat Grimm RH, Leon AS, Hunninghake DB, Lenz K, Hannan P, Blackburn H. Effects of thiazide diuretics on plasma lipids and lipoproteins in mildly hypertensive patients: a double-blind controlled trial. Ann Intern Med. 1981;94(1):7–11.CrossRefPubMed Grimm RH, Leon AS, Hunninghake DB, Lenz K, Hannan P, Blackburn H. Effects of thiazide diuretics on plasma lipids and lipoproteins in mildly hypertensive patients: a double-blind controlled trial. Ann Intern Med. 1981;94(1):7–11.CrossRefPubMed
10.••
Zurück zum Zitat Roush GC, Holford TR, Guddati AK. Chlorthalidone compared with hydrochlorothiazide in reducing cardiovascular events: systematic review and network meta-analyses. Hypertension. 2012;59(6):1110–7. This meta-analysis suggests that chlorthalidone reduces cardiovascular endpoints more than hydrochlorothiazide does. CrossRefPubMed Roush GC, Holford TR, Guddati AK. Chlorthalidone compared with hydrochlorothiazide in reducing cardiovascular events: systematic review and network meta-analyses. Hypertension. 2012;59(6):1110–7. This meta-analysis suggests that chlorthalidone reduces cardiovascular endpoints more than hydrochlorothiazide does. CrossRefPubMed
11.
Zurück zum Zitat Dorsch MP, Gillespie BW, Erickson SR, Bleske BE, Weder AB. Chlorthalidone reduces cardiovascular events compared with hydrochlorothiazide: a retrospective cohort analysis. Hypertension. 2011;57(4):689–94.CrossRefPubMed Dorsch MP, Gillespie BW, Erickson SR, Bleske BE, Weder AB. Chlorthalidone reduces cardiovascular events compared with hydrochlorothiazide: a retrospective cohort analysis. Hypertension. 2011;57(4):689–94.CrossRefPubMed
12.
Zurück zum Zitat Wright JM, Musini VM. First-line drugs for hypertension. Cochrane Datab Syst Rev. 2009;3:CD001841. Wright JM, Musini VM. First-line drugs for hypertension. Cochrane Datab Syst Rev. 2009;3:CD001841.
13.
Zurück zum Zitat Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:b1665. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:b1665.
14.
Zurück zum Zitat Waeber B, Rotaru C, Feihl F. Position of indapamide, a diuretic with vasorelaxant activities, in antihypertensive therapy. Expert Opin Pharmacother. 2012;13(10):1515–26.CrossRefPubMed Waeber B, Rotaru C, Feihl F. Position of indapamide, a diuretic with vasorelaxant activities, in antihypertensive therapy. Expert Opin Pharmacother. 2012;13(10):1515–26.CrossRefPubMed
15.
Zurück zum Zitat Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens. 2003;16(11 Pt 1):925–30.CrossRefPubMed Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens. 2003;16(11 Pt 1):925–30.CrossRefPubMed
16.
Zurück zum Zitat Jansen PM, Danser AHJ, Imholz BP, van den Meiracker AH. Aldosterone-receptor antagonism in hypertension. J Hypertens. 2009;27(4):680–91.CrossRefPubMed Jansen PM, Danser AHJ, Imholz BP, van den Meiracker AH. Aldosterone-receptor antagonism in hypertension. J Hypertens. 2009;27(4):680–91.CrossRefPubMed
17.
Zurück zum Zitat Struthers A, Krum H, Williams GH. A comparison of the aldosterone-blocking agents eplerenone and spironolactone. Clin Cardiol. 2008;31(4):153–8.CrossRefPubMed Struthers A, Krum H, Williams GH. A comparison of the aldosterone-blocking agents eplerenone and spironolactone. Clin Cardiol. 2008;31(4):153–8.CrossRefPubMed
18.
Zurück zum Zitat Swift PA, MacGregor GA. The epithelial sodium channel in hypertension: genetic heterogeneity and implications for treatment with amiloride. Am J Pharmacogenomics. 2004;4(3):161–8.CrossRefPubMed Swift PA, MacGregor GA. The epithelial sodium channel in hypertension: genetic heterogeneity and implications for treatment with amiloride. Am J Pharmacogenomics. 2004;4(3):161–8.CrossRefPubMed
19.
Zurück zum Zitat Saha C, Eckert GJ, Ambrosius WT, Chun TY, Wagner MA, Zhao Q, et al. Improvement of blood pressure with inhibition of the epithelial sodium channel in blacks with hypertension. Hypertension. 2005;46(3):481–7.CrossRefPubMed Saha C, Eckert GJ, Ambrosius WT, Chun TY, Wagner MA, Zhao Q, et al. Improvement of blood pressure with inhibition of the epithelial sodium channel in blacks with hypertension. Hypertension. 2005;46(3):481–7.CrossRefPubMed
20.
Zurück zum Zitat Baker EH, Duggal A, Dong Y, Ireson NJ, Wood M, Markandu ND, et al. Amiloride, a specific drug for hypertension in black people with T594M variant? Hypertension. 2002;40(1):13–7.CrossRefPubMed Baker EH, Duggal A, Dong Y, Ireson NJ, Wood M, Markandu ND, et al. Amiloride, a specific drug for hypertension in black people with T594M variant? Hypertension. 2002;40(1):13–7.CrossRefPubMed
21.
Zurück zum Zitat Licht JH, Haley RJ, Pugh B, Lewis SB. Diuretic regimens in essential hypertension. A comparison of hypokalemic effects, BP control, and cost. Arch Intern Med. 1983;143(9):1694–9.CrossRefPubMed Licht JH, Haley RJ, Pugh B, Lewis SB. Diuretic regimens in essential hypertension. A comparison of hypokalemic effects, BP control, and cost. Arch Intern Med. 1983;143(9):1694–9.CrossRefPubMed
23.
Zurück zum Zitat Taler SJ, Textor SC, Augustine JE. Resistant hypertension: comparing hemodynamic management to specialist care. Hypertension. 2002;39(5):982–8.CrossRefPubMed Taler SJ, Textor SC, Augustine JE. Resistant hypertension: comparing hemodynamic management to specialist care. Hypertension. 2002;39(5):982–8.CrossRefPubMed
24.
Zurück zum Zitat van Brummelen P, Schalekamp M, de Graeff J. Influence of sodium intake on hydrochlorothiazide-induced changes in blood pressure, serum electrolytes, renin and aldosterone in essential hypertension. Acta Med Scand. 1978;204(3):151–7.PubMed van Brummelen P, Schalekamp M, de Graeff J. Influence of sodium intake on hydrochlorothiazide-induced changes in blood pressure, serum electrolytes, renin and aldosterone in essential hypertension. Acta Med Scand. 1978;204(3):151–7.PubMed
25.
Zurück zum Zitat Erwteman TM, Nagelkerke N, Lubsen J, Koster M, Dunning AJ. Beta blockade, diuretics, and salt restriction for the management of mild hypertension: a randomised double blind trial. Br Med J (Clin Res Ed). 1984;289(6442):406–9.CrossRef Erwteman TM, Nagelkerke N, Lubsen J, Koster M, Dunning AJ. Beta blockade, diuretics, and salt restriction for the management of mild hypertension: a randomised double blind trial. Br Med J (Clin Res Ed). 1984;289(6442):406–9.CrossRef
26.
Zurück zum Zitat Singer DR, Markandu ND, Sugden AL, Miller MA, MacGregor GA. Sodium restriction in hypertensive patients treated with a converting enzyme inhibitor and a thiazide. Hypertension. 1991;17(6 Pt 1):798–803.PubMed Singer DR, Markandu ND, Sugden AL, Miller MA, MacGregor GA. Sodium restriction in hypertensive patients treated with a converting enzyme inhibitor and a thiazide. Hypertension. 1991;17(6 Pt 1):798–803.PubMed
27.
Zurück zum Zitat Mann SJ, Gerber LM. Estimation of 24-hour sodium excretion from spot urine samples. J Clin Hypertens (Greenwich). 2010;12(3):174–80.CrossRef Mann SJ, Gerber LM. Estimation of 24-hour sodium excretion from spot urine samples. J Clin Hypertens (Greenwich). 2010;12(3):174–80.CrossRef
28.
Zurück zum Zitat Vaughan ED, Laragh JH, Gavras I, Bühler FR, Gavras H, Brunner HR, et al. Volume factor in low and normal renin essential hypertension. Treatment with either spironolactone or chlorthalidone. Am J Cardiol. 1973;32(4):523–32.CrossRefPubMed Vaughan ED, Laragh JH, Gavras I, Bühler FR, Gavras H, Brunner HR, et al. Volume factor in low and normal renin essential hypertension. Treatment with either spironolactone or chlorthalidone. Am J Cardiol. 1973;32(4):523–32.CrossRefPubMed
29.
Zurück zum Zitat Niarchos AP, Laragh JH. Effects of diuretic therapy in low-, normal- and high-renin isolated systolic systemic hypertension. Am J Cardiol. 1984;53(6):797–801.CrossRefPubMed Niarchos AP, Laragh JH. Effects of diuretic therapy in low-, normal- and high-renin isolated systolic systemic hypertension. Am J Cardiol. 1984;53(6):797–801.CrossRefPubMed
30.
Zurück zum Zitat Brooks CS, Johnson CA, Kotchen JM, Kotchen TA. Diuretic therapies in low renin and normal renin essential hypertension. Clin Pharmacol Ther. 1977;22(1):14–20.PubMed Brooks CS, Johnson CA, Kotchen JM, Kotchen TA. Diuretic therapies in low renin and normal renin essential hypertension. Clin Pharmacol Ther. 1977;22(1):14–20.PubMed
31.
Zurück zum Zitat Egan BM, Basile JN, Rehman SU, Davis PB, Grob CH, Riehle JF, et al. Plasma renin test-guided drug treatment algorithm for correcting patients with treated but uncontrolled hypertension: a randomized controlled trial. Am J Hypertens. 2009;22(7):792–801.CrossRefPubMed Egan BM, Basile JN, Rehman SU, Davis PB, Grob CH, Riehle JF, et al. Plasma renin test-guided drug treatment algorithm for correcting patients with treated but uncontrolled hypertension: a randomized controlled trial. Am J Hypertens. 2009;22(7):792–801.CrossRefPubMed
32.
Zurück zum Zitat Khosla N, Chua DY, Elliott WJ, Bakris GL. Are chlorthalidone and hydrochlorothiazide equivalent blood-pressure-lowering medications? J Clin Hypertens (Greenwich). 2005;7(6):354–6.CrossRef Khosla N, Chua DY, Elliott WJ, Bakris GL. Are chlorthalidone and hydrochlorothiazide equivalent blood-pressure-lowering medications? J Clin Hypertens (Greenwich). 2005;7(6):354–6.CrossRef
33.
Zurück zum Zitat Calhoun DA, White WB. Effectiveness of the selective aldosterone blocker, eplerenone, in patients with resistant hypertension. J Am Soc Hypertens. 2008;2(6):462–8.CrossRefPubMed Calhoun DA, White WB. Effectiveness of the selective aldosterone blocker, eplerenone, in patients with resistant hypertension. J Am Soc Hypertens. 2008;2(6):462–8.CrossRefPubMed
34.
Zurück zum Zitat Kohvakka A, Eisalo A, Manninen V. Maintenance of potassium balance during diuretic therapy. Acta Med Scand. 1979;205(4):319–24.PubMed Kohvakka A, Eisalo A, Manninen V. Maintenance of potassium balance during diuretic therapy. Acta Med Scand. 1979;205(4):319–24.PubMed
35.
Zurück zum Zitat BD, Lane DA. Amiloride 10 mg is less effective than spironolactone 25 mg in patients with hypertension resistant to a multidrug regime including an angiotensin-blocking agent. J Hypertens. 2007; [Online]. Available: http://ovidsp.tx.ovid.com/sp-3.13.0b/ovidweb.cgi?QS2=434f4e1a73d37e8cc073476c0173649e8203932b0dd05cfa175bb55163dbdec33213968f9c85955f6834399b6aeccdecc24279d7fdd2b71fe84a2ba8da0fbaffbd4c4ed7012f6df47df77bc7c6138436ba7a74cff1aa375d8bb957b2c8fe081cb8a3d6be835de0bf170c68835ebce8060bf402d3104daebc3c069e5bb030cf900a578211cdb34b8b12eaf017d8556f1219986cf4bf53f8761f07f44be28ab5f082447773de9779564a02255579b4a5e881d3f09fb74c5d25ee30404e00fbfff30ea10b7e204ce5fe59929ab68e521423acbe34e0b4b016e3e6d32a68d55abc6. [Accessed: 05-Sep-2014]. BD, Lane DA. Amiloride 10 mg is less effective than spironolactone 25 mg in patients with hypertension resistant to a multidrug regime including an angiotensin-blocking agent. J Hypertens. 2007; [Online]. Available: http://​ovidsp.​tx.​ovid.​com/​sp-3.​13.​0b/​ovidweb.​cgi?​QS2=​434f4e1a73d37e8c​c073476c0173649e​8203932b0dd05cfa​175bb55163dbdec3​3213968f9c85955f​6834399b6aeccdec​c24279d7fdd2b71f​e84a2ba8da0fbaff​bd4c4ed7012f6df4​7df77bc7c6138436​ba7a74cff1aa375d​8bb957b2c8fe081c​b8a3d6be835de0bf​170c68835ebce806​0bf402d3104daebc​3c069e5bb030cf90​0a578211cdb34b8b​12eaf017d8556f12​19986cf4bf53f876​1f07f44be28ab5f0​82447773de977956​4a02255579b4a5e8​81d3f09fb74c5d25​ee30404e00fbfff3​0ea10b7e204ce5fe​59929ab68e521423​acbe34e0b4b016e3​e6d32a68d55abc6. [Accessed: 05-Sep-2014].
36.
Zurück zum Zitat Agarwal R, Sinha AD. Thiazide diuretics in advanced chronic kidney disease. J Am Soc Hypertens. 5 Suppl 6:299–308. Agarwal R, Sinha AD. Thiazide diuretics in advanced chronic kidney disease. J Am Soc Hypertens. 5 Suppl 6:299–308.
37.
Zurück zum Zitat Agarwal R, Sinha AD, Pappas MK, Ammous F. Chlorthalidone for poorly controlled hypertension in chronic kidney disease: an interventional pilot study. Am J Nephrol. 2014;39(2):171–82.CrossRefPubMed Agarwal R, Sinha AD, Pappas MK, Ammous F. Chlorthalidone for poorly controlled hypertension in chronic kidney disease: an interventional pilot study. Am J Nephrol. 2014;39(2):171–82.CrossRefPubMed
38.
Zurück zum Zitat Wollam GL, Tarazi RC, Bravo EL, Dustan HP. Diuretic potency of combined hydrochlorothiazide and furosemide therapy in patients with azotemia. Am J Med. 1982;72(6):929–38.CrossRefPubMed Wollam GL, Tarazi RC, Bravo EL, Dustan HP. Diuretic potency of combined hydrochlorothiazide and furosemide therapy in patients with azotemia. Am J Med. 1982;72(6):929–38.CrossRefPubMed
39.
Zurück zum Zitat Ram CV, Garrett BN, Kaplan NM. Moderate sodium restriction and various diuretics in the treatment of hypertension. Arch Intern Med. 1981;141(8):1015–9.CrossRefPubMed Ram CV, Garrett BN, Kaplan NM. Moderate sodium restriction and various diuretics in the treatment of hypertension. Arch Intern Med. 1981;141(8):1015–9.CrossRefPubMed
40.
Zurück zum Zitat Cohn JN, Kowey PR, Whelton PK, Prisant LM. New guidelines for potassium replacement in clinical practice: a contemporary review by the National Council on Potassium in Clinical Practice. Arch Intern Med. 2000;160(16):2429–36.CrossRefPubMed Cohn JN, Kowey PR, Whelton PK, Prisant LM. New guidelines for potassium replacement in clinical practice: a contemporary review by the National Council on Potassium in Clinical Practice. Arch Intern Med. 2000;160(16):2429–36.CrossRefPubMed
41.
Zurück zum Zitat Ramsay LE, Boyle P, Ramsay MH. Factors influencing serum potassium in treated hypertension. Q J Med. 1977;46(184):401–10.PubMed Ramsay LE, Boyle P, Ramsay MH. Factors influencing serum potassium in treated hypertension. Q J Med. 1977;46(184):401–10.PubMed
42.
Zurück zum Zitat Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA. 1991;24 Suppl 265:3255–64. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA. 1991;24 Suppl 265:3255–64.
43.
Zurück zum Zitat Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;23 Suppl 288:2981–29. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;23 Suppl 288:2981–29.
44.
Zurück zum Zitat Mann SJ. The silent epidemic of thiazide-induced hyponatremia. J Clin Hypertens (Greenwich). 2008;10(6):477–84.CrossRef Mann SJ. The silent epidemic of thiazide-induced hyponatremia. J Clin Hypertens (Greenwich). 2008;10(6):477–84.CrossRef
46.
48.
Zurück zum Zitat Smith SM, Anderson SD, Wen S, Gong Y, Turner ST, Cooper-Dehoff RM, et al. Lack of correlation between thiazide-induced hyperglycemia and hypokalemia: subgroup analysis of results from the pharmacogenomic evaluation of antihypertensive responses (PEAR) study. Pharmacotherapy. 2009;29(10):1157–65.CrossRefPubMedCentralPubMed Smith SM, Anderson SD, Wen S, Gong Y, Turner ST, Cooper-Dehoff RM, et al. Lack of correlation between thiazide-induced hyperglycemia and hypokalemia: subgroup analysis of results from the pharmacogenomic evaluation of antihypertensive responses (PEAR) study. Pharmacotherapy. 2009;29(10):1157–65.CrossRefPubMedCentralPubMed
49.
Zurück zum Zitat Garcá Puig J, Miranda ME, Mateos F, Herrero E, Lavilla P, Gil A. Hydrochlorothiazide versus spironolactone: long-term metabolic modifications in patients with essential hypertension. J Clin Pharmacol. 1991;31:455–61. Garcá Puig J, Miranda ME, Mateos F, Herrero E, Lavilla P, Gil A. Hydrochlorothiazide versus spironolactone: long-term metabolic modifications in patients with essential hypertension. J Clin Pharmacol. 1991;31:455–61.
50.
Zurück zum Zitat Falch DK, Schreiner A. The effect of spironolactone on lipid, glucose and uric acid levels in blood during long-term administration to hypertensives. Acta Med Scand. 1983;213(1):27–30.CrossRefPubMed Falch DK, Schreiner A. The effect of spironolactone on lipid, glucose and uric acid levels in blood during long-term administration to hypertensives. Acta Med Scand. 1983;213(1):27–30.CrossRefPubMed
51.
Zurück zum Zitat Shafi T, Appel LJ, Miller ER, Klag MJ, Parekh RS. Changes in serum potassium mediate thiazide-induced diabetes. Hypertension. 2008;52(6):1022–9.CrossRefPubMedCentralPubMed Shafi T, Appel LJ, Miller ER, Klag MJ, Parekh RS. Changes in serum potassium mediate thiazide-induced diabetes. Hypertension. 2008;52(6):1022–9.CrossRefPubMedCentralPubMed
52.
Zurück zum Zitat Zillich AJ, Garg J, Basu S, Bakris GL, Carter BL. Thiazide diuretics, potassium, and the development of diabetes: a quantitative review. Hypertension. 2006;48(2):219–24.CrossRefPubMed Zillich AJ, Garg J, Basu S, Bakris GL, Carter BL. Thiazide diuretics, potassium, and the development of diabetes: a quantitative review. Hypertension. 2006;48(2):219–24.CrossRefPubMed
53.
Zurück zum Zitat Achhammer I, Metz P. Low dose loop diuretics in essential hypertension. Experience with torasemide. Drugs. 1991;41(3):80–91.CrossRefPubMed Achhammer I, Metz P. Low dose loop diuretics in essential hypertension. Experience with torasemide. Drugs. 1991;41(3):80–91.CrossRefPubMed
54.
Zurück zum Zitat McAdams DeMarco MA, Maynard JW, Baer AN, Gelber AC, Young JH, Alonso A, et al. Diuretic use, increased serum urate levels, and risk of incident gout in a population-based study of adults with hypertension: the Atherosclerosis Risk in Communities cohort study. Arthritis Rheum. 2012;64(1):121–9.CrossRefPubMedCentralPubMed McAdams DeMarco MA, Maynard JW, Baer AN, Gelber AC, Young JH, Alonso A, et al. Diuretic use, increased serum urate levels, and risk of incident gout in a population-based study of adults with hypertension: the Atherosclerosis Risk in Communities cohort study. Arthritis Rheum. 2012;64(1):121–9.CrossRefPubMedCentralPubMed
55.
Zurück zum Zitat Bruderer S, Bodmer M, Jick SS, Meier CR. Use of diuretics and risk of incident gout: a population-based case–control study. Arthritis Rheumatol (Hoboken, NJ). 2014;66(1):185–96.CrossRef Bruderer S, Bodmer M, Jick SS, Meier CR. Use of diuretics and risk of incident gout: a population-based case–control study. Arthritis Rheumatol (Hoboken, NJ). 2014;66(1):185–96.CrossRef
56.
Zurück zum Zitat Jeunemaitre X, Chatellier G, Kreft-Jais C, Charru A, DeVries C, Plouin PF, et al. Efficacy and tolerance of spironolactone in essential hypertension. Am J Cardiol. 1987;60(10):820–5.CrossRefPubMed Jeunemaitre X, Chatellier G, Kreft-Jais C, Charru A, DeVries C, Plouin PF, et al. Efficacy and tolerance of spironolactone in essential hypertension. Am J Cardiol. 1987;60(10):820–5.CrossRefPubMed
57.
Zurück zum Zitat Matsumura K, Arima H, Tominaga M, Ohtsubo T, Sasaguri T, Fujii K, et al. Effect of losartan on serum uric acid in hypertension treated with a diuretic: the COMFORT study. Clin Exp Hypertens. 2014;1–5. Matsumura K, Arima H, Tominaga M, Ohtsubo T, Sasaguri T, Fujii K, et al. Effect of losartan on serum uric acid in hypertension treated with a diuretic: the COMFORT study. Clin Exp Hypertens. 2014;1–5.
58.
Zurück zum Zitat Choi HK, Soriano LC, Zhang Y, Rodríguez LAG. Antihypertensive drugs and risk of incident gout among patients with hypertension: population based case–control study. BMJ. 2012;344:d8190.CrossRefPubMedCentralPubMed Choi HK, Soriano LC, Zhang Y, Rodríguez LAG. Antihypertensive drugs and risk of incident gout among patients with hypertension: population based case–control study. BMJ. 2012;344:d8190.CrossRefPubMedCentralPubMed
59.
Zurück zum Zitat Wasnich RD, Benfante RJ, Yano K, Heilbrun L, Vogel JM. Thiazide effect on the mineral content of bone. N Engl J Med. 1983;309:344–7.CrossRefPubMed Wasnich RD, Benfante RJ, Yano K, Heilbrun L, Vogel JM. Thiazide effect on the mineral content of bone. N Engl J Med. 1983;309:344–7.CrossRefPubMed
60.
Zurück zum Zitat LaCroix AZ, Wienpahl J, White LR, Wallace RB, Scherr PA, George LK, et al. Thiazide diuretic agents and the incidence of hip fracture. N Engl J Med. 1990;322:286–90.CrossRefPubMed LaCroix AZ, Wienpahl J, White LR, Wallace RB, Scherr PA, George LK, et al. Thiazide diuretic agents and the incidence of hip fracture. N Engl J Med. 1990;322:286–90.CrossRefPubMed
61.
Zurück zum Zitat Leppla D, Browne R, Hill K, Pak CY. Effect of amiloride with or without hydrochlorothiazide on urinary calcium and saturation of calcium salts. J Clin Endocrinol Metab. 1983;57:920–4.CrossRefPubMed Leppla D, Browne R, Hill K, Pak CY. Effect of amiloride with or without hydrochlorothiazide on urinary calcium and saturation of calcium salts. J Clin Endocrinol Metab. 1983;57:920–4.CrossRefPubMed
62.
Zurück zum Zitat TRR, Mosenkis A. Muscle cramps and diuretic therapy. J Clin Hypertens (Greenwich, Conn). 2005;7:134–5. TRR, Mosenkis A. Muscle cramps and diuretic therapy. J Clin Hypertens (Greenwich, Conn). 2005;7:134–5.
63.
Zurück zum Zitat Garrison SR, Dormuth CR, Morrow RL, Carney GA, Khan KM. Nocturnal leg cramps and prescription use that precedes them: a sequence symmetry analysis. Arch Intern Med. 2012;172(2):120–6.CrossRefPubMed Garrison SR, Dormuth CR, Morrow RL, Carney GA, Khan KM. Nocturnal leg cramps and prescription use that precedes them: a sequence symmetry analysis. Arch Intern Med. 2012;172(2):120–6.CrossRefPubMed
64.
Zurück zum Zitat Garrison SR, Allan GM, Sekhon RK, Musini VM, Khan KM. Magnesium for skeletal muscle cramps. Cochrane Datab Syst Rev. 2012;9:CD009402. Garrison SR, Allan GM, Sekhon RK, Musini VM, Khan KM. Magnesium for skeletal muscle cramps. Cochrane Datab Syst Rev. 2012;9:CD009402.
65.
Zurück zum Zitat Katzberg HD, Khan AH, So YT. Assessment: symptomatic treatment for muscle cramps (an evidence-based review): report of the therapeutics and technology assessment subcommittee of the American academy of neurology. Neurology. 2010;74(8):691–6.CrossRefPubMed Katzberg HD, Khan AH, So YT. Assessment: symptomatic treatment for muscle cramps (an evidence-based review): report of the therapeutics and technology assessment subcommittee of the American academy of neurology. Neurology. 2010;74(8):691–6.CrossRefPubMed
67.
Zurück zum Zitat Strom BL, Schinnar R, Apter AJ, Margolis DJ, Lautenbach E, Hennessy S, et al. Absence of cross-reactivity between sulfonamide antibiotics and sulfonamide nonantibiotics. N Engl J Med. 2003;349(17):1628–35.CrossRefPubMed Strom BL, Schinnar R, Apter AJ, Margolis DJ, Lautenbach E, Hennessy S, et al. Absence of cross-reactivity between sulfonamide antibiotics and sulfonamide nonantibiotics. N Engl J Med. 2003;349(17):1628–35.CrossRefPubMed
68.
Zurück zum Zitat Jamerson K, Weber MA, Bakris GL, Dahlöf B, Pitt B, Shi V, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359(23):2417–28.CrossRefPubMed Jamerson K, Weber MA, Bakris GL, Dahlöf B, Pitt B, Shi V, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359(23):2417–28.CrossRefPubMed
69.
Zurück zum Zitat Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med. 2009;122(3):290–300.CrossRefPubMed Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med. 2009;122(3):290–300.CrossRefPubMed
70.
Zurück zum Zitat Bakris GL, Oparil S, Purkayastha D, Yadao AM, Alessi T, Sowers JR. Randomized study of antihypertensive efficacy and safety of combination aliskiren/valsartan vs valsartan monotherapy in hypertensive participants with type 2 diabetes mellitus. J Clin Hypertens (Greenwich). 2013;15(2):92–100.CrossRef Bakris GL, Oparil S, Purkayastha D, Yadao AM, Alessi T, Sowers JR. Randomized study of antihypertensive efficacy and safety of combination aliskiren/valsartan vs valsartan monotherapy in hypertensive participants with type 2 diabetes mellitus. J Clin Hypertens (Greenwich). 2013;15(2):92–100.CrossRef
71.
Zurück zum Zitat Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358(15):1547–59.CrossRefPubMed Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358(15):1547–59.CrossRefPubMed
72.
Zurück zum Zitat Cappuccio FP, Markandu ND, Singer DR, Buckley MG, Miller MA, Sagnella GA, et al. A double-blind crossover study of the effect of concomitant diuretic therapy in hypertensive patients treated with amlodipine. Am J Hypertens. 1991;4(4 Pt 1):297–302.PubMed Cappuccio FP, Markandu ND, Singer DR, Buckley MG, Miller MA, Sagnella GA, et al. A double-blind crossover study of the effect of concomitant diuretic therapy in hypertensive patients treated with amlodipine. Am J Hypertens. 1991;4(4 Pt 1):297–302.PubMed
73.
Zurück zum Zitat Cappuccio FP, Singer DR, MacGregor GA. The effects of thiazides plus calcium channel blockers. JAMA. 8 Suppl 264:971–3. Cappuccio FP, Singer DR, MacGregor GA. The effects of thiazides plus calcium channel blockers. JAMA. 8 Suppl 264:971–3.
74.
Zurück zum Zitat Burris JF, Weir MR, Oparil S, Weber M, Cady WJ, Stewart WH. An assessment of diltiazem and hydrochlorothiazide in hypertension. Application of factorial trial design to a multicenter clinical trial of combination therapy. JAMA. 1990;263(11):1507–12.CrossRefPubMed Burris JF, Weir MR, Oparil S, Weber M, Cady WJ, Stewart WH. An assessment of diltiazem and hydrochlorothiazide in hypertension. Application of factorial trial design to a multicenter clinical trial of combination therapy. JAMA. 1990;263(11):1507–12.CrossRefPubMed
75.
Zurück zum Zitat Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension. 2003;42(6):1206–52.CrossRefPubMed Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension. 2003;42(6):1206–52.CrossRefPubMed
77.
Zurück zum Zitat Cosín J, Díez J. Torasemide in chronic heart failure: results of the TORIC study. Eur J Heart Fail. 2002;4(4):507–13.CrossRefPubMed Cosín J, Díez J. Torasemide in chronic heart failure: results of the TORIC study. Eur J Heart Fail. 2002;4(4):507–13.CrossRefPubMed
78.••
Zurück zum Zitat Bikdeli B, Strait KM, Dharmarajan K, Partovian C, Coca SG, Kim N, et al. Dominance of furosemide for loop diuretic therapy in heart failure: time to revisit the alternatives? J Am Coll Cardiol. 2013;61(14):1549–50. This meta-analysis suggests that chlorthalidone reduces cardiovascular endpoints more than hydrochlorothiazide does. CrossRefPubMedCentralPubMed Bikdeli B, Strait KM, Dharmarajan K, Partovian C, Coca SG, Kim N, et al. Dominance of furosemide for loop diuretic therapy in heart failure: time to revisit the alternatives? J Am Coll Cardiol. 2013;61(14):1549–50. This meta-analysis suggests that chlorthalidone reduces cardiovascular endpoints more than hydrochlorothiazide does. CrossRefPubMedCentralPubMed
79.
Zurück zum Zitat Baumgart P. Torasemide in comparison with thiazides in the treatment of hypertension. Cardiovasc Drugs Ther. 1993;7 Suppl 1:63–8.CrossRefPubMed Baumgart P. Torasemide in comparison with thiazides in the treatment of hypertension. Cardiovasc Drugs Ther. 1993;7 Suppl 1:63–8.CrossRefPubMed
80.
Zurück zum Zitat Dunn CJ, Fitton A, Brogden RN. Torasemide. An update of its pharmacological properties and therapeutic efficacy. Drugs. 1995;49(1):121–42.CrossRefPubMed Dunn CJ, Fitton A, Brogden RN. Torasemide. An update of its pharmacological properties and therapeutic efficacy. Drugs. 1995;49(1):121–42.CrossRefPubMed
Metadaten
Titel
Personalizing the Diuretic Treatment of Hypertension: the Need for More Clinical and Research Attention
verfasst von
Samuel J. Mann
Michael E. Ernst
Publikationsdatum
01.04.2015
Verlag
Springer US
Erschienen in
Current Hypertension Reports / Ausgabe 4/2015
Print ISSN: 1522-6417
Elektronische ISSN: 1534-3111
DOI
https://doi.org/10.1007/s11906-015-0542-4

Weitere Artikel der Ausgabe 4/2015

Current Hypertension Reports 4/2015 Zur Ausgabe

Hypertension and Obesity (E Reisin, Section Editor)

Obesity and Left Ventricular Hypertrophy: The Hypertension Connection

Secondary Hypertension: Nervous System Mechanisms (J Bisognano, Section Editor)

Vagal Modulation of Hypertension

Novel Treatments for Hypertension (T Unger, Section Editor)

Antiplatelet Treatment in Essential Hypertension: Where Do We Stand?

Blood Pressure Monitoring and Management (J Cockcroft, Section Editor)

The Role of Telemedicine in Hypertension Management: Focus on Blood Pressure Telemonitoring

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.